- Aquest esdeveniment ja ha passat.
21 març 2023 @ 09:30 - 12:00
Accelerating drug discovery using advanced protein and antibody development platforms
Cancer is a disease characterized by misregulation of cell proliferation and differentiation. Moreover, cancer cells often escape the immune system’s attacks by expressing inhibitory ligands and molecules. Immunotherapies such as immune checkpoint blockade, chimeric antigen receptor T-cell (CAR-T) therapies, antibodies to cancer antigens and cytokine therapy overcome the immune escape and offer a promising treatment for several cancers, as well as autoimmune diseases. Therefore, manufacturing high-quality therapeutic proteins and antibodies has become very important to meet medical needs. However, low protein yield, protein aggregation and degradation are common issues during therapeutic-protein production.
Sino Biological has provided many strategies to solve these difficulties such as codon optimization, single amino acid mutation and improvement of protein purification. Using several antibody development platforms and different protein production methods, Sino Biological has generated many therapeutic antibodies such as neutralization antibodies against SARS-CoV-2 or RSV; several immune checkpoint blockade antibodies including anti-PD-1, anti-CTLA-4 and anti-TIM-3 antibodies. Utilizing comprehensive cell-based assays, they have demonstrated therapeutic functions of these antibodies in vitro. Additionally, they have developed many long half-life therapeutic cytokines. Combining these cytokines with immune checkpoint blockade has shown synergistic effects to inhibit cancer progression, which can be applied on the preclinic trials and are benefits for cancer treatment in vivo.